|Day Low/High||0.17 / 0.20|
|52 Wk Low/High||0.14 / 0.98|
Imagine a derailed freight train carrying dumpsters on fire. That's an accurate description of the Northwest Bio 10-K filed Monday night.
Northwest's inability to resolve the problems that froze the DCVax-L clinical trial -- and management's refusal to offer a public explanation for why it happened -- triggered the company's collapse.
Northwest Biotherapeutics, a regular visitor to the capital markets, has negotiated a note payment schedule with Whitebox Advisors.
Process Now Moving Forward Toward Data Lock
TheStreet's biotech columnist offers his own report card on biotech stocks.
Trial Enrolled 331 Patients;
Trial to Be Led By University Of Mainz Center of Excellence
Using Northwest Bio as an example, I'm going to teach you how to read clinical trial data to find red flags and bad stuff biotechs don't want you to see.
Dr. Marnix Bosch, Chief Technical Officer, Presented
Shares and Warrants To Be Cancelled and Reduced; MFN To Be Removed from Contracts
The cancer immunotherapy company's cash position has plunged to the point where it may no longer be capable of paying its operating expenses.
Progress Also Reported On Additional Nasdaq Compliance Issue
A defrocked analyst brushes off the serious problems weighing on Northwest Bio. Instead, he jacks the tired 'blame the shorts' excuse to another level.
Leading Experts in Immunotherapies and Oncology From Both the US and Europe
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
New Developments Relating to Phase I and II Trials, Scientific Advisory Board and Nasdaq Compliance
These under-$10 stocks are making big moves higher. Here's how to trade them from here.
TheStreet's Senior Columnist Adam Feuerstein answers reader questions about biotech stocks.